The
Daily
Fix
For load:
Garlic Butter Shrimp Stir-Fry with Zucchini & Peppers
Semaglutide Fails in Alzheimer’s Trial — A New Direction Emerges
Why GLP-1 drugs fell short and why ketogenic therapy may hold promise.
Back squat 5-5-5 reps
Shoulder press 5-5-5 reps
Deadlift 5-5-5 reps
Shrimp stir-fried in garlic butter with crisp zucchini and bell peppers for a light, protein-packed, meal.
Ingredients
For the Stir-Fry:
8 oz shrimp, peeled and deveined
1 Tbsp butter (for cooking)
1 cup zucchini, sliced into half-moons
½ cup red bell pepper, thinly sliced
½ cup broccoli florets
1 Tbsp scallions, chopped
2 cloves garlic, minced
1 tsp ginger, grated
1 tsp coconut aminos (or tamari, optional)
Salt and pepper, to taste
Optional Garnish:
1 tsp sesame seeds
1 tsp olive oil (for drizzling)
Macronutrients
Protein: 50g
Fat: 20g
Carbs: 9g
Preparation
Pat shrimp dry and season lightly with salt and pepper.
Heat ½ Tbsp butter in a skillet or wok over medium-high. Add shrimp and cook 2–3 minutes per side until pink and opaque. Remove and set aside.
In the same skillet, add remaining ½ Tbsp butter. Stir-fry zucchini, bell pepper, broccoli, garlic, and ginger for 4–5 minutes until crisp-tender.
Return shrimp to the skillet. Add coconut aminos (if using) and toss everything together for 1–2 minutes until well coated.
Plate shrimp stir-fry, garnish with scallions, sesame seeds, and a light drizzle of olive oil.
Go heavy.
Post loads for each lift to comments.
A major randomized trial from Novo Nordisk found that semaglutide did not slow cognitive decline in early Alzheimer’s disease, contradicting earlier observational studies that hinted at potential benefit. The result underscores that medication-driven metabolic improvements alone may be insufficient once neurodegeneration is underway.
Alzheimer’s is marked by the brain’s reduced ability to use glucose for energy, even decades before symptoms appear. Yet the brain can still use ketones efficiently. Early research on ketogenic diets and therapeutic ketosis shows improvements in brain energy, cognition, and daily functioning, suggesting that providing an alternative fuel source may address a key deficit drugs haven’t solved.
While GLP-1 medications remain useful for metabolic disease, their failure in Alzheimer’s highlights the need to invest in nutritional and metabolic therapies, which may offer meaningful benefits despite limited funding and lack of pharmaceutical backing.
GET THE FULL FIX AT BROKENSCIENCE.ORG/FIX
SUNDAY 251214